198 related articles for article (PubMed ID: 36439058)
1. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer.
Aquino-Acevedo AN; Knochenhauer H; Castillo-Ocampo Y; Ortiz-León M; Rivera-López YA; Morales-López C; Cruz-Robles ME; Hernández-Cordero ER; Russell S; Whitaker R; Bonilla-Claudio M; Chen DT; Dutil J; Gaillard SL; Yi JS; Previs RA; Armaiz-Pena GN
Brain Behav Immun Health; 2022 Dec; 26():100558. PubMed ID: 36439058
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
3. Gansui Banxia decoction modulates immune-inflammatory homeostasis to ameliorate malignant ascites in rats.
Huo M; Wang T; Li M; Li N; Chen S; Xiu L; Yu X; Liu H; Zhong G
Phytomedicine; 2024 Mar; 125():155246. PubMed ID: 38262142
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells.
Kampan NC; Madondo MT; McNally OM; Stephens AN; Quinn MA; Plebanski M
Front Immunol; 2017; 8():1482. PubMed ID: 29163543
[TBL] [Abstract][Full Text] [Related]
5. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
7. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.
Khan ANH; Emmons TR; Magner WJ; Alqassim E; Singel KL; Ricciuti J; Eng KH; Odunsi K; Tomasi TB; Lee K; Abrams SI; Mesa C; Segal BH
Cancer Immunol Immunother; 2022 Oct; 71(10):2355-2369. PubMed ID: 35166871
[TBL] [Abstract][Full Text] [Related]
8. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
Kamat K; Krishnan V; Dorigo O
Br J Cancer; 2022 Oct; 127(6):1026-1033. PubMed ID: 35750747
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
11. Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer.
Zhang J; He T; Yin Z; Shang C; Xue L; Guo H
Front Oncol; 2022; 12():864021. PubMed ID: 35875098
[TBL] [Abstract][Full Text] [Related]
12. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
13. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
Front Immunol; 2020; 11():89. PubMed ID: 32184777
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Microenvironment in High Grade Serous Ovarian Cancer.
Nwani NG; Sima LE; Nieves-Neira W; Matei D
Cancers (Basel); 2018 Aug; 10(8):. PubMed ID: 30103384
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer.
Li Y; Wang W; Wang D; Zhang L; Wang X; He J; Cao L; Li K; Xie H
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553542
[TBL] [Abstract][Full Text] [Related]
16. Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.
Tran E; Nielsen JS; Wick DA; Ng AV; Johnson LD; Nesslinger NJ; McMurtrie E; Webb JR; Nelson BH
PLoS One; 2010 Dec; 5(12):e15625. PubMed ID: 21203522
[TBL] [Abstract][Full Text] [Related]
17. GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.
Worley BL; Kim YS; Mardini J; Zaman R; Leon KE; Vallur PG; Nduwumwami A; Warrick JI; Timmins PF; Kesterson JP; Phaëton R; Lee NY; Walter V; Endres L; Mythreye K; Aird KM; Hempel N
Redox Biol; 2019 Jul; 25():101051. PubMed ID: 30509602
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
19. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
20. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
